News
Scancell has linked iSCIB1+ to a 69% response rate in advanced melanoma, lead | Scancell has linked iSCIB1+ to a 69% response ...
Clinical Trials Arena on MSN8d
Scancell taps melanoma mAb for progression following positive Phase II results
Following the Phase II faceoff between two of Scancell’s lead melanoma immunotherapy candidates, the biotech has selected ...
SCOPE trial of SCIB1/iSCIB1+ plus standard of care shows excellent results encompassing efficacy, durability, immune responses and safety ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback